Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
EBMT 2022
;
At #ASH23, @Eddie_Cliff (@BrighamWomens) shared insights from the POLARIX trial, revealing differences in the efficacy of R-CHP between subgroups of patients with #DLBCL.
Watch here:
👉
#Lymphoma #LYsm #TrialUpdate #CTSM #HemOnc @ASH_Hematology
POLARIX: R-CHP is more effective in the subgroup of DLBCL patients with activated B-cell origin
Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, speaks on the POLARIX trial (NCT03274492), focusi...
ow.ly
Please spread the message and book your calendar
@COMyCongress @TheIACH
Want to hear about the highlights in the field of CLL from #ASH23, with a focus on the FLAIR study?
Then check out our interview with @DrMDavids of @DanaFarber here:
👉
#CLLsm #LeuSM #Leukemia #CTSM #HemOnc #ASH23 @ASH_hematology
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the highlights in the space of chronic lym...
ow.ly
🎥 @thomas_cluzeau of @CHUdeNice talks on the preliminary results of the VENTOGRAPH trial of AZA, VEN, and DLI in MDS and AML following AHSCT relapse.
Watch here:
👉
#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc #ASH23 @ASH_hematology
VENTOGRAPH trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following AHSCT
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the preliminary findings of the ...
ow.ly
Prof. John Gribben (@QMBCI) gave a wonderful insight into axi-cel in R/R #FollicularLymphoma at #ASH23 with an updated comparison of ZUMA-5 and SCHOLAR-5.
Watch here:
👉
#LYMsm #Lymphoma #NonHodgkinLymphoma #ImmunoOnc #HemOnc @ASH_hematology
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, comments on the updated 4-year ...
ow.ly
EBMT 2022
At #ASH23, @Eddie_Cliff (@BrighamWomens) shared insights from the POLARIX trial, revealing differences in the efficacy of R-CHP between subgroups of patients with #DLBCL.
Watch here:
👉
#Lymphoma #LYsm #TrialUpdate #CTSM #HemOnc @ASH_Hematology
POLARIX: R-CHP is more effective in the subgroup of DLBCL patients with activated B-cell origin
Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, speaks on the POLARIX trial (NCT03274492), focusi...
ow.ly
Please spread the message and book your calendar
@COMyCongress @TheIACH
Want to hear about the highlights in the field of CLL from #ASH23, with a focus on the FLAIR study?
Then check out our interview with @DrMDavids of @DanaFarber here:
👉
#CLLsm #LeuSM #Leukemia #CTSM #HemOnc #ASH23 @ASH_hematology
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the highlights in the space of chronic lym...
ow.ly
🎥 @thomas_cluzeau of @CHUdeNice talks on the preliminary results of the VENTOGRAPH trial of AZA, VEN, and DLI in MDS and AML following AHSCT relapse.
Watch here:
👉
#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc #ASH23 @ASH_hematology
VENTOGRAPH trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following AHSCT
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the preliminary findings of the ...
ow.ly
Prof. John Gribben (@QMBCI) gave a wonderful insight into axi-cel in R/R #FollicularLymphoma at #ASH23 with an updated comparison of ZUMA-5 and SCHOLAR-5.
Watch here:
👉
#LYMsm #Lymphoma #NonHodgkinLymphoma #ImmunoOnc #HemOnc @ASH_hematology
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, comments on the updated 4-year ...
ow.ly
